The increasing tuberculosis (TB) disease prevalence is a major factor that is expected to drive growth of the global pyrazinamide market. For instance, according to the National Center for Biotechnology Information in 2019, total 8,920 number of TB disease new cases were provisionally reported in the U.S. according to same source, the rate of TB is around 2.7 per 100,000 persons. Moreover, TB is a major burden across the globe. According to TB Facts report organization data, in 2018, in the U.S, the cost of treating drug sensitive TB was US$ 49,000; treatment costs for MDR-TB averaged US$ 393,000; and treatment costs for XDR TB averaged US$ 758,000.
Global Pyrazinamide Market - Impact of Coronavirus (COVID-19) Pandemic
The spread of the novel coronavirus has hampered growth of the healthcare industry. In December 2019, a cluster of pneumonia cases were reported by Chinese health authorities in China’s Wuhan City. The pneumonia causative agent was identified as a novel coronavirus named COVID-19. This virus spread rapidly across the globe causing a concerning number of fatalities. In March, 2020, the World Health Organization (WHO) declared COVID-19 as a global pandemic and suggested implementation of strict measures to minimize the spread of this disease. The pandemic has slowed growth of the healthcare sector and led to a disturbance in the supply chain of pharmaceutical drugs.
Moreover, governments across various countries have implemented nationwide lockdowns to curb the spread of COVID-19. Similarly, in various countries across the world, healthcare companies are facing problems of continuing their supply chain operations. The slowdown of the supply chain has also impacted growth of the global pyrazinamide market.
The global pyrazinamide market is estimated to be valued at US$ 143.9 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).
Fig. 1. Global Pyrazinamide Market Share (%) Analysis, By Patient Type, 2020
Global Pyrazinamide Market- Restraints
Increasing pyrazinamide drug resistant TB infection is a major factor that is expected to restrain growth of the global pyrazinamide market.
|Base Year:||2019||Market Size in 2020:||US$ 143.9 Mn|
|Historical Data for:||2017 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||4.6%||2027 Value Projection:||US$ 163.1 Mn|
Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
|Restraints & Challenges:||
Global Pyrazinamide Market: Regional Analysis
On the basis of region, the global pyrazinamide market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to witness significant growth in the global pyrazinamide market, owing to increasing number of TB patient across the U.S. and Canada respectively. For instance, in 2019, according to data of the Centers for Disease Control and Prevention states that, around 8,916 number of TB cases were reported in the U.S. Similarly, in 2017, according to the Canada government data, there were around 1,796 number of TB cases reported in Canada, when compared with around 1,750 number of TB cases in 2016, indicates a 2.6% increase.
Additionally, in Europe, growth of the pyrazinamide market is attributed to high number of TB patients. For instance, according to European Centre for Disease Prevention and Control data around 55,337 TB cases were reported in year 2017, which was around rate of 10.7 per 100,000 population.
Fig.2. Global Pyrazinamide Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Global Pyrazinamide Market- Competitive Landscape
Key players operating in the global pyrazinamide market include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, and, City Chemical.
Pyrazinamide (PZA) is a medication used to treat tuberculosis. Moreover, for active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. Pyrazinamide kills non-replicating persister cells that other medication of TB fail to kill, and for which it became important drug for inclusion in any drug combinations for treating drug susceptible and drug-resistant TB such as MDR-TB. It acts variably compared to other antibiotics by inhibiting energy production, trans-translation, and co-enzyme A required for persister survival. The increasing mutation in drug targeted gene is marking bacterial strain more resistant to PZA drug. The recently panD mutations gene was found along with pncA or rpsA mutations gene in bacterial resistant strains.
The high burden of TB is expected to drive growth of the market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa, which accounted for two thirds of the new TB cases.
The increasing global burden of TB is expected to drive the pyrazinamide market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.
Moreover, according to the WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$ 12 billion in additional economic costs and lost productivity. Thus, increasing healthcare spending on treatment of TB is expected to drive growth of the market.
Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.
Moreover, increasing investments in R&D activities for development of novel therapies for treatment of TB is expected to restrain growth of the pyrazinamide drugs market. For instance, according to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017, with an increase of 6% (or US$ 46 million), compared to US$ 726 million in 2016.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients